Press release
Non-hodgkin's Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis, DelveInsight | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovec
Non-hodgkin's Lymphoma Pipeline Insights
Non-hodgkin's Lymphoma Overview:
Non-Hodgkin Lymphoma (NHL) is a cancer of the lymphatic system, commonly affecting the lymph nodes. It encompasses a group of over 86 closely related cancers, collectively known as lymphoid neoplasms, as outlined in the 2016 World Health Organization classification. While these types share common traits, they differ in appearance, molecular features, growth patterns, impact on the body, and treatment responses.
NHL is the seventh most common cancer among adults in the United States, with its incidence nearly doubling between 1975 and 2013. Over 72,000 new cases were estimated in 2016. Symptoms often include swollen lymph nodes (usually painless), fever, night sweats, unexplained weight loss, and fatigue. However, these symptoms can also result from non-lymphoma conditions. Medical attention is recommended if symptoms persist for more than two weeks or are severe enough to disrupt daily life.
Request for a detailed insights report on Non-hodgkin's Lymphoma pipeline insights @ https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Non-hodgkin's Lymphoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-hodgkin's Lymphoma Therapeutics Market.
Key Takeaways from the Non-hodgkin's Lymphoma Pipeline Report
DelveInsight's Non-hodgkin's Lymphoma pipeline report depicts a robust space with 200+ active players working to develop 220+ pipeline therapies for Non-hodgkin's Lymphoma treatment.
In April 2024, Rituxan (rituximab) was approved for treating various blood cancers, autoimmune diseases, and inflammatory conditions, including follicular lymphoma (FL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), mature B-cell acute leukemia (B-AL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and pemphigus vulgaris (PV). RITUXAN HYCELA, a formulation combining rituximab with Halozyme's hyaluronidase human ENHANZE technology, is approved for adults with previously untreated or relapsed/refractory FL, untreated DLBCL, and both untreated and treated CLL.
In March 2024, Lantern Pharma began dosing two participants in a Phase Ia/Ib clinical trial for LP-284, an experimental drug for relapsed or refractory NHL. LP-284 is a novel small molecule designed to eliminate cancer cells with mutations in DNA damage repair pathways through a synthetically lethal mechanism.
Key Non-hodgkin's Lymphoma companies such as Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, and others are evaluating new drugs for Non-hodgkin's Lymphoma to improve the treatment landscape.
Promising Non-hodgkin's Lymphoma pipeline therapies in various stages of development include Mosunetuzumab, Tisagenlecleucel, Capivasertib, BI-1206, HMPL-760, and others.
Non-hodgkin's Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Non-hodgkin's Lymphoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-hodgkin's Lymphoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-hodgkin's Lymphoma market.
Download our free sample page report on Non-hodgkin's Lymphoma pipeline insights @ https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Non-hodgkin's Lymphoma Emerging Drugs
Mosunetuzumab: Hoffmann-la Roche
Tisagenlecleucel: Novartis
Capivasertib: AstraZeneca
BI-1206: BioInvent
HMPL-760: Hutchmed
Non-hodgkin's Lymphoma Companies
More than 200 prominent companies are actively working on developing therapies for Non-Hodgkin Lymphoma. Among them, Hoffmann-La Roche has drug candidates in the most advanced stage of development, Phase III.
DelveInsight's report covers around 220+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Non-hodgkin's Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Non-hodgkin's Lymphoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Non-hodgkin's Lymphoma Therapies and Key Companies: Non-hodgkin's Lymphoma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Non-hodgkin's Lymphoma Pipeline Therapeutic Assessment
• Non-hodgkin's Lymphoma Assessment by Product Type
• Non-hodgkin's Lymphoma By Stage
• Non-hodgkin's Lymphoma Assessment by Route of Administration
• Non-hodgkin's Lymphoma Assessment by Molecule Type
Download Non-hodgkin's Lymphoma Sample report to know in detail about the Non-hodgkin's Lymphoma treatment market @ Non-hodgkin's Lymphoma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Non-hodgkin's Lymphoma Current Treatment Patterns
4. Non-hodgkin's Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-hodgkin's Lymphoma Late-Stage Products (Phase-III)
7. Non-hodgkin's Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-hodgkin's Lymphoma Discontinued Products
13. Non-hodgkin's Lymphoma Product Profiles
14. Non-hodgkin's Lymphoma Key Companies
15. Non-hodgkin's Lymphoma Key Products
16. Dormant and Discontinued Products
17. Non-hodgkin's Lymphoma Unmet Needs
18. Non-hodgkin's Lymphoma Future Perspectives
19. Non-hodgkin's Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Non-hodgkin's Lymphoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-hodgkin's Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis, DelveInsight | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovec here
News-ID: 3818754 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
